Laidlaw Capital Markets
Laidlaw Capital Markets offers our clients alternatives to highly structured financings that often paralyze a company’s capital structure. WE ARE BRAND COGNIZANT and strive to perform outreach to a broad base of Healthcare and Technology fundamental investors. Our team has extensive experience in executing transactions for both debt and equity in the private and public markets.
Our objective is to perform in a way where we cultivate long term relationships with exciting and growth oriented companies. We “roll up our sleeves” and help our clients add top tier shareholders, increase their liquidity profile and get their story out in a meaningful and thoughtful way. As you will see in our Case Studies, we are able to leverage our diverse institutional and retail network of sophisticated investors to deliver superior results across a variety of deal structures.
The Laidlaw Capital Markets Team has collaborated with organizations in developing strategies and goals on an individual company basis as well as assisting them in navigating the path to achieve their desired results. We have a demonstrated track record of providing the best funding available for companies that have work to do prior to moving upstream. As your company continues to grow and mature, the Laidlaw Capital Markets Team stays with you and will make introductions to Healthcare Centric Funds and Investment Banks. We believe you will the find the Laidlaw Capital Markets Brand to be true partner in your growth.
We would happy to provide you with Management References at many of the companies we have assisted.
- Initial Public Offering (IPO)
- Follow-On Offering
- Confidentially Marketed Public Offering (CMPO)
- Registered Direct (RD)
- PIPE Transaction
- Private Placement
- Block trade
Soleno Therapeutics
Common Stock & Concurrent Private Placement
$129,000,000
.
Co-Manager
October 2023
BioSig Technologies
PIPE Transaction
$2,500,000
.
At The Market Offering
May 2023
Serve Robotics Inc
Secured Convertible Debenture
$3,000,000
.
Introducing Broker
April 2023
PD Theramostics
Series A Financing
$3,000,000
.
Exclusive Placement Agent
April 2023
Viking Therapeutics
Follow-On Offering
$287,500,000
.
Co-Manager
March 2023
Guerilla RF, Inc
PIPE Transaction
$9,200,000
.
Exclusive Placement Agent
February 2023
The NFT Gaming Company
Initial Public Offering
$7,000,000
.
Lead Book Runner
February 2023
BioSig Technologies
PIPE Transaction
$7,300,000
.
Introducing Broker
January 2023
Hoth Therapeutics
PIPE Transaction
$10,000,000
.
Financial Advisor
January 2023
NLS Pharmaceutics
Private Placement
$10,000,000 of up to $30,000,000
Investor: BVF Partners L.P.
Exclusive Introducing Broker
December 2022
Perfect Moment
Private Placement
$6,000,000
.
Exclusive Placement Agent
October 2022
NLS Pharmaceuticals
Private Placement
$4,000,000
.
Sole Placement Agent
October 2022
Silo Pharma
Follow-On Offering
$5,750,000
.
Sole Book runner
September 2022
Amesite, Inc
Registered Direct Offering
$2,300,000
Sole Placement Agent
August 2022
Perfect Moment
Secured Convertible Note
.
$10,000,000
Exclusive Placement Agent
June 2022
BioSig Technologies
Follow-On Offering
Common Stock
$3,500,000
Sole Book-Runner
June 2022
Soleno Therapeutics
Follow-On Offering
Common Stock
and Warrants
$15,000,000
Co-Manager
March 2022
Cohen & Steers
Initial Public Offering
Common Stock
$367,886,900
Initial Public Offering
February 2022
Amesite, Inc
Follow-On Offering
Common Stock
$3,000,000
Sole-Book Runner
February 2022
Cingulate, Inc.
Initial Public Offering
Common Stock and Warrants
$25,000,000
Co-Lead Bookrunner
December 2021
MEI
Pharma
PIPE Transaction
Follow-on Offering
Common Stock
$52,325,000
Financial Advisor
December 2021
Guggenheim Active Allocation Fund.
Initial Public Offering
Common Stock
$655,000,000
Co-Manager
November 2021
EyePoint Pharmaceuticals
Follow-On Offering
Common Stock
.$115,000,000
Financial Advisor
November 2021
aTyr Pharma Inc.
Follow-On Offering
Common Stock
$86,250,000
Lead Manager
September 2021
Blackrock ESG Capital Allocation Trust
Initial Public Offering
Common Stock
$2,040,000,000
Co-Manager
September 2021
BioSig Technologies
Follow-On Offering
Common Stock
$10,000,000
Sole Book-Runner
July 2021
Aldeyra Therapeutics
Follow-On Offering
Common Stock
.
$125,000,000
Co-Manager
April 2021
iCAD Inc.
Follow-On Offering
Common Stock
.
$25,000,000
Co-Manager
March 2021
EyePoint Pharmaceuticals
Follow-On Offering
Common Stock
.
$115,000,000
Financial Advisor
February 2021
Evoke Pharma
Follow-On Offering
Common Stock
.
$14,375,000
Sole Book-Runner
January 2021
Affimed
Follow-On Offering
Common Stock
.
$115,00,000
Co-Manager
January 2021
Curis Inc.
Follow-On Offering
Common Stock
.
$169,625,000
Lead Manager
December 2020
Delcath Systems
Follow-On Offering
Common Stock
.
$22,247,000
Financial Advisor
December 2020
Amesite, Inc
Initial Public Offering
Common Stock
.
$15,00,000
Sole Book Runner
Sept 2020
Arcturus Therapeutics
Follow-On Offering
Common Stock
.
$173,000,000
Financial Advisor
July 2020
Soleno Therapeutics
Follow-On Offering
Common Stock
.
$50,000,000
Co-Manager
June 2020
ViralClear Pharmaceuticals
Private Placement
Common Stock
.
$10,800,000
Introducing Broker
May 2020
Delcath Systems
Follow-On Offering
Common Stock
.
$22,000,000
Co-Lead Manager
May 2020
Arcturus Therapeutics
Follow-On Offering
Common Stock
.
$70,000,000
Financial Advisor
April 2020
Hoth Therapeutics
Follow-On
Common Stock
.
$5,000,000
Sole-Book Runner
March 2020
EyePoint Pharmaceuticals
Follow-On Offering
Common Stock
.
$21,800,000
Co-Manager
February 2020
BioSig Technologies
Follow-On Offering
Common Stock
$10,000,000
Sole Book-Runner
February 2020
Ziopharm Oncology
Follow-On Offering
Common Stock
.
$90,000,000
Co-Manager
February 2020
Beyond Air
Follow-On Offering
Common Stock
.
$10,500,000
Financial Advisor
December 2019
Molecular
Templates, Inc.
Follow-On Offering
Common Stock & Convertible Preferred Stock.
$50,000,000
Financial Advisor
November 2019
Affimed
Follow-On Offering
Common Stock
.
$34,500,000
Co-Manager
November 2019
Soleno Therapeutics
Follow-On Offering
Common Stock
.
$15,400,000
Co-Manager
October 2019
Hoth Therapeutics
Private Placement
Common Stock
.
$2,037,000
Exclusive Placement Agent
September 2019
Noxopharm, Ltd
Funding Facility
$26,000,000
Sole Financial Advisor
July 2019
Icad, Inc
Follow-On Offering
Common Stock
.
$9,000,000
Financial Advisor
June 2019
EyePoint Pharmaceuticals
Follow-On Offering
Common Stock
.
$20,000,000
Co-Manager
March 2019
Hoth Therapeutics
Initial Public Offering
Common Stock
.
$7,000,000
Sole Book Runner
February 2019
Taiwan
Liposome Company
Initial Public Offering
Common Stock
.
$21,750,000
Co-Manager
November 2018
Tiziana
Life Sciences
Initial Public Offering
Common Stock
.
$7,000,000
Sole Book Runner
November 2018
Aldeyra Therapeutics
Follow-On Offering
Common Stock
.
$72,187,500
Co-Manager
September 2018
Molecular
Templates, Inc.
Follow-On Offering
Common Stock
.
$45,100,000
Lead Manager
September 2018
Viking
Therapeutics
Follow-On Offering
Common Stock
.
$175,800,000
Financial Advisor
September 2018
BioSig Technologies
PIPE Transaction
Common Stock
& Warrants
$6,000,000
Introducing Broker
August 2018
Aridis Pharmaceuticals
Initial Public Offering
Common Stock
$26,000,000
Co-Manager
August 2018
Athenex, Inc
PIPE Transaction
Common Stock, Warrants & Senior Debt
$100,000,000
Exclusive Placement Agent
July 2018
Viking
Therapeutics
Follow-On Offering
Common Stock
$78,000,000
Financial Advisor
June 2018
Sesen
Bio
Follow-On Offering
Common Stock
.
$48,000,000
Financial Advisor
May 2018
MEI
Pharma
PIPE Transaction
Common Stock and Warrants
$75,000,000
Co-Placement Agent
May 2018
AIT Therapeutics
PIPE Transaction
Warrants
.
$9,820,154.54
Exclusive Placement Agent
February 2018
Hoth Therapeutics
Private Placement
Series A
Preferred Warrants
$3,102,480
Exclusive Placement Agent
February 2018
Affimed
Follow-On Offering
Common Stock
$23,000,000
Financial Advisor
February 2018
Gemphire
Follow-On Offering
Common Stock
$22,000,000
Co-Manager
February 2018
Athenex, Inc
Follow-On Offering
Common Stock
$65,575,000
Co-Manager
January 2018
Fennec
Pharmaceuticals
Follow-On Offering
Common Stock
$20,000,000
Financial Advisor
December 2017
Cytori
Therapeutics
Rights Offering
Convertible Preferred
Stock and Warrants
$10,000,000
Financial Advisor
November 2017
Onconova
Therapeutics
Registered Direct
Common Stock
$1,380,000
Sole Placement Agent
November 2017
ADMA Biologics
Follow-On Offering
Common Stock
$36,500,000
Financial Advisor
November 2017
Asterias
Biotherapeutics
Registered Direct
Common Stock
$10,400,000
Financial Advisor
October 2017
Flexion Therapeutics
Follow-On Offering
Common Stock
$122,400,000
Financial Advisor
October 2017
Aldeyra Therapeutics
Follow-On Offering
Common Stock
$28,800,000
Lead Manager
September 2017
MabVax
Therapeutics, Inc
Registered Direct
Common Stock
$2,000,000
Sole Placement Agent
September 2017
Repros
Therapeutics
Confidentially Marketed
Public Offering
Common Stock and Warrants
$3,000,000
Sole Book-Runner
May 2017
MabVax
Therapeutics, Inc
Follow-On Offering
Common and
Preferred Stock
$4,100,000
Sole Book-Runner
May 2017
Flexion
Therapeutics
Convertible Note
$175,000,000
Financial Advisor
May 2017
Onconova
Therapeutics
Confidentially Marketed
Public Offering
Common Stock
$5,963,517
Sole Book Runner
April 2017
BioSig Technologies
PIPE Transaction
Common Stocks
& Warrants
$4,349,954
Exclusive Placement Agent
March 2017
Therapix
Biosciences
Initial Public Offering
Common Stock
$13,800,000
Sole Book Runner
March 2017
AIT Therapeutics
PIPE Transaction,
Common Stock
and Warrants
$10,200,000
Placement Agent
March 2017
Aldeyra Therapeutics
Follow-On Offering
Common Stock
$10,000,000
Lead Manager
February 2017
Medovex Corporation
PIPE Transaction
Common Stock & Warrants
$3,022,000
Exclusive Placement Agent
February 2017
Protea Biosciences Group, Inc
Convertible
Debenture
$1,736,000
Exclusive Placement Agent
September 2016
Medovex
Corporation
PIPE Transaction
Common Stock
& Warrants
$1,398,033
Placement Agent
April 2016
MabVax
Therapeutics, Inc
Follow-On Offering
Common Stock
& Warrants
$9,438,750
Sole Book-Runner
August 2016
Alimera Sciences
Follow-On Offering
Common Stock
$25,000,000
Co-Manager
August 2016
ImmunoCellular
Follow-On Offering
Common Stocks
& Warrants
$7,400,000
Lead Manager
August 2016
ADMA Biologics
Follow-On Offering
Common Stock
$14,200,000
Financial Advisor
April 2016
Durect Corporation
Follow-On Offering
Common Stock
$15,000,000
Co-Manager
April 2016
ContraVir
Pharmaceuticals
Follow-On Offering
Common Stock
& Warrants
$7,000,000
Sole Book-Runner
March 2016